Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome everyone joining today's Neurocrin Biosciences fourth quarter and fiscal year 2025 earnings call. At this time all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time please press star 1 on your telephone keypad. Please note this call is being recorded and We are standing by if you should need any assistance. And it is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead. Happy Wednesday to everyone, and welcome to Nurocrine Biosciences' fourth quarter and 2025 year-end earnings call. With me today are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Kaswani, Chief Medical Officer, and for the first time, we are very pleased to be joined by Samir Sedanti, Vice President of Strategy and Corporate Development. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we'll be happy to address any questions. With that, Kyle, take it away. Thanks, Todd. Good afternoon, everyone. A hallmark of a healthy company is the strength of the foundation beneath it. As Neurocrine enters 2026, our foundation is stronger than at any point in our more than 30-year history, and it continues to strengthen. With growing enterprise-wide momentum and strategic balance diversification, Neurocrine has entered a new era of meaningful growth led by our first and best-in-class commercial brands. Aggressiv...